|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours.
|
28373262 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL).
|
30530801 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of ibrutinib, a first-in-class oral inhibitor of Bruton tyrosine kinase (BTK), for the treatment of relapsed/refractory (R/R) and/or TP53 mutated patients with CLL.
|
31732977 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
|
31512258 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral irreversible inhibitor of Bruton's tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia.
|
29891001 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase, has altered the treatment perspective of chronic lymphocytic leukemia and showed modest activity against several types of non-Hodgkin's lymphomas.
|
31142233 |
2020 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL).
|
28972595 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase approved for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and refractory Waldenstrom's disease.
|
31287200 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL).
|
30842083 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
|
29317636 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL).
|
31141631 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, the expression of IBTK gene progressively increases from indolent to aggressive stage of chronic lymphocytic leukemia and decreases in disease remission after therapy.
|
30975981 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).
|
24869598 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
|
30421802 |
2019 |
|
Mantle cell lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Mantle cell lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
|
30421802 |
2019 |
|
Mantle cell lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This first-in-class inhibitor of Bruton's tyrosine kinase has become a standard treatment for patients with CLL and MCL.
|
30061088 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Deletions of CDKN2A/B (28%) and IBTK (23%) were frequent events in relapsed DLBCLs.
|
27276707 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b/> In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the central nervous system.
|
28864640 |
2017 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia.
|
30785921 |
2019 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
|
30421802 |
2019 |
|
Small Lymphocytic Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
|
31512258 |
2019 |
|
Small Lymphocytic Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours.
|
28373262 |
2017 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton's tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX).
|
31371481 |
2019 |